scholarly journals Methylation ofDLEC1Promoter Is a Predictor for Recurrence in Chinese Patients with Gastric Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Xiaobing Ye ◽  
Gang Feng ◽  
Nanlin Jiao ◽  
Chun Pu ◽  
Guohai Zhao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Esophageal Cancer ◽  
Cancer Patients ◽  
Promoter Methylation ◽  
Chinese Patients ◽  
Promoter Regions ◽  
Specific Pcr ◽  
Gastric Cancer Patients ◽  
Clinicopathological Variables ◽  
Valuable Predictor

Purpose. To investigate promoter methylation in the deleted in lung and esophageal cancer 1 (DLEC1) gene in Chinese patients with gastric cancer.Methods. A total of 227 patients with gastric cancer were enrolled. The methylations of the promoter regions ofDLEC1and ACTB were determined using quantitative methylation-specific PCR. TheDLEC1methylation was compared to the clinicopathological variables of gastric cancer.Results.DLEC1methylation was not associated with the clinicopathological variables of gastric cancer. Patients withDLEC1-hypermethylated gastric cancer had significantly higher recurrence rate than those withDLEC1-hypomethylated gastric cancer (P=0.025;hazard ratio=2.43).Conclusions. Methylation of DELC1 promoter may be a valuable predictor for recurrence in Chinese patients with gastric cancer.

scholarly journals Anastomosis for distal gastrectomy in Chinese patients: uncut roux-Y or roux-Y?

BMC Surgery ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
B. K. Sah ◽  
J. Li ◽  
C. Yan ◽  
C. Li ◽  
M. Yan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Postoperative Complications ◽  
Cancer Patients ◽  
Distal Gastrectomy ◽  
Controlled Trial ◽  
Group Versus ◽  
Anastomosis Group ◽  
Chinese Patients ◽  
Gastrojejunal Anastomosis ◽  
Gastric Cancer Patients

Abstract Background An appropriate method of anastomosis is crucial for gastric cancer patients who require gastrojejunal anastomosis. Surgeons have proposed different types of modified gastrojejunostomies in the last two decades. We focused on two types of standard anastomosis, i.e., Uncut Roux-Y and Roux-Y gastrojejunostomies, and compared the differences in immediate postoperative complications between the two types. Methods This is a retrospective study on 236 gastric cancer patients who underwent curative distal gastrectomy with gastrojejunal Roux-Y or Uncut Roux-Y anastomosis for six consecutive years. Immediate postoperative complications were compared between the two groups. The authors discussed the causes of the significant complications and their management. Results There was no difference in demographics between the two groups (92 Roux-y Versus 144 Uncut Roux-y). The overall complication rate was 20.8% with 1.4% anastomotic leakage in the Uncut Roux-Y group versus 33.7% with 7.6% anastomotic failures in the Roux-Y group (p < 0.05). More abdominal infections occurred in the Roux-Y anastomosis group compared with the Uncut Roux-Y anastomosis group (p < 0.05). Duration of postoperative stay was significantly longer in patients with Roux-y anastomosis group (p < 0.05). Conclusions Considering the surgical simplicity and postoperative complications, the Uncut Roux-Y is a better choice for anastomosis in patients with gastric cancer undergoing gastrojejunostomy. A well-designed large cohort in a multi-centre randomized controlled trial is necessary to support these findings and compare other aspects.

scholarly journals Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer

2018 ◽  
Vol 28 (2) ◽  
Author(s):  
Amin Abbasi ◽  
Sahar Heydari
Keyword(s):  
Gastric Cancer ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Methylation Status ◽  
Blood Samples ◽  
Specific Pcr ◽  
Expression Rate ◽  
And Performance ◽  
Gastric Cancer Patients ◽  
Gene Age

As gastric cancer has no exclusive signals in its initial phases, it is usually diagnosed in advanced phases. Although many researches have been conducted on methylation and diagnosis of cancer’s markers, the methylation and expression of Reprimo gene and its correlation with gastric cancer has not been thoroughly studied. Methylation of Reprimo promoter is a repetitive procedure exclusive to cancer which nullifies its expression and performance. The present research seeks to study the expression and methylation of Reprimo among people suffering with gastric cancer so that it may be used as a biomarker for early diagnosis. Fifty blood samples taken from healthy people (normal samples) and 50 blood samples obtained from gastric cancer patients were analyzed using Real-Time PCR. The methylation status of the promoter of Reprimo was studied using Methylation Specific PCR technique in normal samples and in gastric cancer Iranian patients. We observed reduction in expression rate of Reprimo in the blood samples of patients suffering with gastric cancer in comparison to normal blood samples. A significant correlation was also observed between the expression rate of this gene, age and methylation of its promoter among patients suffering with gastric cancer and various analysis points to a correlation between reduced expressions of Reprimo gene in gastric cancer patients. In conclusion, reduced expression of Reprimo gene and greater levels of methylation of its promoter seems to be promising biomarkers for early diagnosis of gastric cancer.

scholarly journals Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Peipei Liu ◽  
Úna C. McMenamin ◽  
Andrew D. Spence ◽  
Brian T. Johnston ◽  
Helen G. Coleman ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Esophageal Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Population Based ◽  
Practice Research ◽  
Clinical Practice Research Datalink ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Gastric Cancer Patients

Abstract Background Pre-clinical studies have shown that furosemide slows cancer cell growth by acting on the Na-K-2Cl transporter, particularly for gastric cancer cells. However, epidemiological studies have not investigated furosemide use and mortality in gastroesophageal cancer patients. Consequently, we conducted a population-based study to investigate whether furosemide use is associated with reduced cancer-specific mortality in esophageal/gastric cancer patients. Methods A cohort of patients newly diagnosed with esophageal or gastric cancer between 1998 and 2013 were identified from English cancer registries and linked to the Clinical Practice Research Datalink to provide prescription records and the Office of National Statistics to provide death data up to September 2015. Time-dependant Cox-regression models were used to calculate hazard ratios (HRs) comparing cancer-specific mortality in furosemide users with non-users. Analyses were repeated restricting to patients with common furosemide indications (heart failure, myocardial infarction, edema or hypertension) to reduce potential confounding. Results The cohort contained 2708 esophageal cancer patients and 2377 gastric cancer patients, amongst whom 1844 and 1467 cancer-specific deaths occurred, respectively. Furosemide use was not associated with reduced cancer-specific mortality overall (adjusted HR in esophageal cancer = 1.28, 95% CI 1.10, 1.50 and in gastric cancer = 1.27, 95% CI 1.08, 1.50) or when restricted to patients with furosemide indications before cancer diagnosis (adjusted HR in esophageal cancer = 1.07, 95% CI 0.88, 1.30 and in gastric cancer = 1.18, 95% CI 0.96, 1.46). Conclusions In this large population-based cohort study, furosemide was not associated with reduced cancer-specific mortality in patients with esophageal or gastric cancer.

Association of extensive delayed overmethylation influenced by advanced atrophy with risk for gastric cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 13-13
Author(s):  
Jung Hwan Oh ◽  
Sung Hoon Jung ◽  
DaeYoung Cheung ◽  
Mun Gan Rhyu ◽  
Seung Jin Hong
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Cpg Island ◽  
The Body ◽  
Body Site ◽  
Mucosal Atrophy ◽  
Specific Pcr ◽  
Gastric Cancer Patients ◽  
Cell Phenotypes ◽  
Negative Controls

13 Background: Helicobacter pylori (HP) infection facilitates overmethylation of CpG-island genes, which can be delayed by advanced mucosal atrophy. Delayed overmethylation results in unstable cell phenotypes responsible for gastric cancer. To delineate cancer risk period, the overmethylation period from HP infection to severe atrophy was traced in the gastric cancer and dysplasia. Methods: A pair of normal-appearing mucosal specimens was obtained from the antrum and body of 110 HP-positive and 95 HP-negative controls, 99 cancer patients, and 118 dysplasia patients. Gastric mucosal atrophy was assessed using the endoscopic atrophic border score. Eight CpG-island genes adjacent to Alu (CDH1, ARRDC4, PPARG, TRAPPC2L) and LTR retroelements (MMP2, CDKN2A, RUNX2, RUNX3) and the TFF3 gene lacking CpG island were chosen. The methylation-variable sites in gene-control regions were analyzed using radioisotope-labeling methylation-specific PCR. Results: The antrum-specific TFF3 gene on the antrum tended to be overmethylated earlier than Alu-type CpG-island genes on the body in the HP-positive controls with mild mucosal atrophy (mean age; 50 years vs. 52 years). In moderate atrophic cases, the antrum-site TFF3 overmethylation was delayed four years compared with the whole cases (58 years vs. 54 years) and the Alu-type overmethylation on the body was early detected (49 years). Gastric cancer patients with moderate atrophy induced a late overmethylation on both the antrum and body site (56 and 58 years) and increased LTR-type slow overmethylation (OD, 5.3; 95% CI, 2.0-14.1). Dysplasia patients (65 years) older than gastric cancer sustained an early Alu-type overmethylation on the body site. Conclusions: Moderate atrophy of the gastric mucosa can delay overmethylation of CpG-island genes, which leads to unstable cancer period and subsequent stable dysplasia period.

Sign in / Sign up

Export Citation Format

Share Document